Lu Y, et al. - Researchers performed a general meta-analysis to assess the efficacy of long-term treatment of statins for chronic obstructive pulmonary disease (COPD), and to answer which one is better. For the effect of mortality, inflammatory factors, and lung function index in COPD patients, pooled estimates were produced. They identified the eligible studies from PubMed, Web of Science, Embase, and China National Knowledge Infrastructure, and performed a network meta-analysis to synthetically compare the effectiveness of using different statins in COPD patients. Reduced risks of all-cause mortality, heart disease-related mortality, and COPD acute exacerbation were found in association with statin use in COPD patients in general meta-analysis. In network meta-analysis, the higher cumulative probability in reducing C-reactive protein (CRP) in COPD patients was shown by fluvastatin (97.7%), atorvastatin (68.0%), and rosuvastatin (49.3%) vs other statins. Fluvastatin and atorvastatin more effectively attenuated CRP and pulmonary hypertension (PH) in COPD patients. Overall, statins can attenuate the risk of mortality, the level of CRP, and PH in COPD patients.